leisure time -WSS

leisure time

author：leisure time 2025-10-04 09:36:42 - browse：78528

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： White House touts steps to stem shortages of cancer treatments

entertainment

WSS

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Walmart eyes Medicare Advantage provider ChenMed

How housing is health care on Long Island

Long Covid needs a new name — and a new frame

White House touts steps to stem shortages of cancer treatments

Will generative AI in health care meet the fate of IBM's Dr. Watson?

focus

leisure time

leisure time

Alkermes shareholders re

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Medicare details structure of new drug price negotiation program

New Covid vaccine is recommended for everyone 6 months or older

After affirmative action ruling, medical educators look to 'holistic review'

FDA proposes changes to key medical devices approval pathway

Peter Hotez and the public health issue of online harassment

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Dobbs anniversary: the lost opportunity of abortion as health care

Generate Biomedicines machine learning biotech raises $273M

hotspot

What to make of Biden’s latest efforts on cancer research

States should stop sabotaging methadone treatment reform

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Telehealth for opioid use disorder is lifesaving

How housing is health care on Long Island

Readout LOUD podcast: mifepristone case, GLP

explore

entertainment

focus

knowledge